Tauroursodeoxycholic Acid Alleviates MRC-5 Cell Fibrosis Phenotype Induced By Transforming Growth Factor-β1

The clinical manifestation of lung fibrosis disease is progressive dyspnea and decrease of lung function. It is a chronic diffuse interstitial inflammatory lung disease, characterized by continuous and excessive wound healing reaction. Factors related to fibrosis, especially transforming growth factor-β1, plays a key role in lung fibrosis progress. The searching for appropriate anti-fibrosis drugs and strategy to prevent fibrosis disease has lasted for several decades. But the ideal treatment has not been found until now. Endoplasmic reticulum stress (ER Stress) and unfolded protein response (UPR) are activated in idiopathic pulmonary fibrosis, indicating that ER stress plays a vital role in the progress of pulmonary fibrosis. Tauroursodeoxycholic acid (TUDCA) and Ursodeoxycholic acid (UDCA) can reduce ER stress. To investigate the anesis effect of TUDCA and UDCA on MRC-5 fibrosis phenotype, we built MRC-5 cell fibrosis model and intervened by TUDCA and UDCA. Then we detected the expression of a-SMA and fibronectin, which are the biomarkers of fibrosis. Our study suggests that TUDCA shows prevention and treatment effect on fibrosis phenotype. To summarize, tauroursodeoxycholic acid alleviates MRC-5 cell fibrosis induced by TGF-(31 and might be a potetial anti-fibrosis drug.